BELX Bio-Pharmaceutical Co. Ltd. (BELX) develops innovative botanical new drugs. The lead candidate drug, BEL-X, is in a phase I clinical trial being conducted in Taiwan for advanced stage solid tumor patients. This trial will be completed by September 2020.
Derived from one single plant, BEL-X has an excellent safety profile and offers a novel ROS (reactive oxygen species) balance mechanism of action, which allows the drug to be used alone as well as in combination with current treatment drugs. Pre-clinical animal models show astonishing results in significantly increasing survival and maintaining normal physical activities. These unique characteristics of BEL-X make it a perfect fit for the unmet medical needs in the cancer patients, who need to extend survival and to have good quality of life.BELX’s top management integrates original BEL-X R&D core members from Industrial Technology Research Institute in Taiwan, as well as industrial and academic elites from local and overseas institutes. To protect the core technologies, a total of 47 patents, among which 40 was already approved, has been filed globally. The company plans to raise $17M in 2020 for conducting subsequent clinical trials of BEL-X as well as increasing R&D projects to expand BEL-X’s indications.